Cervical cancer is the third most common cancer in women worldwide. Despite the fact that maximum number of cervical cancer ...

CHIANG MAI, Thailand, Nov. 13, 2025 /PRNewswire/ -- A major step forward in regional collaboration for cancer care was announced today with the launch of Project ACTIVE 2.0 (Advancing Cervical Cancer ...

Department of Gynecology, Huai’an First People’s Hospital, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University, Huai’an, Jiangsu, China Objective: This study aimed to discuss ...

CINCINNATI, Ohio – Maason Smith is up. That means he's playing in Week 2, with the second-year defensive tackle active for the Jaguars against the Cincinnati Bengals at Paycor Stadium Sunday. Veteran ...

Study Achieves Primary and all Secondary Endpoints Demonstrating Clinically Meaningful, Statistically Significant Improvements in hrHPV Negativity at Week 12 as Compared to Placebo 46% of Patients ...

Background: Coexistent cervical intraepithelial neoplasia (CIN) and vaginal intraepithelial neoplasia (VaIN) is problematic, posing challenges for patient management. This study focused on the ...

Please provide your email address to receive an email when new articles are posted on . Only 45.5% of women treated for high-grade cervical dysplasia completed two surveillance co-tests within 30 ...

Introduction High-grade squamous intraepithelial lesions are caused by persistent high-risk human papillomavirus (hr-HPV) infections and are subdivided into cervical intraepithelial neoplasia (CIN) ...

Only 45.5% of patients completed guideline-concordant surveillance within 30 months after treatment for high-grade cervical dysplasia, with one third of those receiving abnormal co-test results. Among ...

DARE-HPV is a proposed treatment for HPV-related cervical diseases, supported by up to $2 million in NIAID grants. Daré Bioscience, Inc. has announced the development of DARE-HPV, an investigational ...